BAY1834845
Sponsors
Bayer
Conditions
Healthy VolunteersImmune Mediated Inflammatory DiseasesInflammationPelvic Inflammatory DiseasePsoriasis
Phase 1
First in Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and to Explore Pharmacodynamics of BAY1834845
CompletedNCT03054402
Start: 2017-02-13End: 2018-03-29Updated: 2019-03-27
Food Effect, Oral & Intravenous Pharmacokinetics and Absolute Bioavailability of BAY1834845 Including Drug-drug Interaction With Methotrexate
CompletedNCT03244462
Start: 2017-08-18End: 2018-07-20Updated: 2019-07-15
A Multiple Dose Study of BAY1834845 in Healthy Male Subjects and in Patients With Psoriasis
CompletedNCT03493269
Start: 2018-04-16End: 2021-02-05Updated: 2021-02-26
A Trial to Learn How BAY1834845 and BAY1830839 Affect Inflammation When Taken by Mouth Twice a Day for 7 Days in a Row in Healthy Male Participants
CompletedNCT05003089
Start: 2021-06-28End: 2022-01-20Updated: 2022-12-16